BIOLOGICAL AND GENETIC RISK FACTORS FOR WEIGHT GAIN AND METABOLIC ABNORMALITIES

体重增加和代谢异常的生物和遗传风险因素

• 批准号: 7719253
• 负责人: CHRISTOPH U CORRELL
• 金额: $ 2.12万
• 依托单位: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-22 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719253
• 关键词: Adolescent; Adverse effects; Adverse event; Antipsychotic Agents; Benefits and Risks; Benign; Biochemical; Biological; Body Composition; Child; Clinical; Computer Retrieval of Information on Scientific Projects Database; Data; Disease; Disruptive Behavior Disorder; Funding; Generations; Glucose; Grant; Health; Imaging Techniques; Institution; Metabolic; Moods; Pharmaceutical Preparations; Public Health; Reporting; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Weight Gain; age group; genetic risk factor; improved; lipid metabolism

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Recent reports of second-generation antipsychotic (SGAP)-associated adverse events have challenged the assumption that these agents have a relatively benign side effect profile. Despite the ever more increasing utilization of SGAPs in children and adolescents, there are only very limited data available about their risk benefit ratio in an age group with particular sensitivity to side effects. As children and adolescents with psychotic, mood and aggressive disorders most often will require long-term treatment with psychiatric medications, a better understanding of the side effect burden and of predictors for these is of crucial importance in order to improve compliance and overall health. This study investigates the effects of second-generation antipsychotic medications on body composition and glucose and lipid metabolism in children and adolescents with psychotic, mood and disruptive behavior disorders. Using clinical, biochemical and imaging techniques, this study aims at the identifiction of clinical and biological predictors as well as mechanisms for these side effects with enormous public health importance.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 第二代抗精神病药（SGAP）相关的不良事件的最新报道提出了以下假设：这些药物具有相对良性的副作用谱。尽管在儿童和青少年中SGAP的利用率越来越高，但在对副作用特别敏感的年龄段中，关于其风险收益率的可用数据非常有限。由于患有精神病，情绪和侵略性疾病的儿童和青少年通常需要长期治疗精神病药物，因此更好地理解副作用负担和这些预测因素对于改善合规性和整体健康至关重要。 这项研究调查了第二代抗精神病药对身体组成，葡萄糖和脂质代谢对患有精神病，情绪和破坏性行为障碍的青少年的影响。 本研究使用临床，生化和成像技术，旨在鉴定临床和生物学预测因子以及这些副作用的机制，具有巨大的公共健康重要性。